Goldman Sachs
LXEO icon

Goldman Sachs’s Lexeo Therapeutics LXEO Stock Holding History

Goldman Sachs’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10M Buy
2,149,612
+199,727
+10% +$1.08M ﹤0.01% 3223
2026
Q1 		$11.2M Buy
1,949,885
+1,168,030
+149% +$8.28M ﹤0.01% 2978
2025
Q4 		$7.76M Buy
781,855
+639,453
+449% +$5.84M ﹤0.01% 3334
2025
Q3 		$946K Buy
142,402
+106,034
+292% +$513K ﹤0.01% 5064
2025
Q2 		$146K Sell
36,368
-42,740
-54% -$141K ﹤0.01% 5746
2025
Q1 		$275K Sell
79,108
-11,793
-13% -$52.2K ﹤0.01% 5507
2024
Q4 		$598K Buy
90,901
+14,150
+18% +$111K ﹤0.01% 5139
2024
Q3 		$694K Buy
76,751
+49,898
+186% +$595K ﹤0.01% 4872
2024
Q2 		$431K Buy
26,853
+3,294
+14% +$47.8K ﹤0.01% 4910
2024
Q1 		$369K Buy
+23,559
New +$368K ﹤0.01% 4879

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Goldman Sachs's LXEO Position: Q2 2026 in Review

Goldman Sachs increased its Lexeo Therapeutics (LXEO) stake by 10% in Q2 2026, buying an estimated $1.08M and bringing the position to 2,149,612 shares worth $10M. The position accounts for ﹤0.01% of the portfolio, ranked #3223.

Goldman Sachs first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.2M in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Goldman Sachs held 2,149,612 shares of Lexeo Therapeutics worth $10M as of Q2 2026.
  • Goldman Sachs bought 199,727 Lexeo Therapeutics shares in Q2 2026, an estimated $1.08M.
  • Lexeo Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3223 holding.
  • Goldman Sachs first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Goldman Sachs's Lexeo Therapeutics position peaked at $11.2M in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.